e232502.full.pdf (221.31 kB)
Low-dose naltrexone as a treatment for chronic fatigue syndrome
Version 2 2023-06-12, 08:06
Version 1 2023-06-10, 01:11
journal contribution
posted on 2023-06-12, 08:06 authored by Monica Jane Bolton, Bryan Paul Chapman, Harm van MarwijkHarm van MarwijkNaltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Although only small-scale clinical trials have been performed, these suggest efficacy in several diseases including Crohn’s disease, fibromyalgia and Gulf War Illness. Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people with chronic fatigue syndrome. This condition is characterised by chronic profound fatigue, postexertional malaise, pain and autonomic and neurocognitive disturbances. This series of three case reports compiled by people with long-term ill-health due to chronic fatigue syndrome shows the range of responses they observed when taking LDN, from life changing to a reduction in some symptoms only. Treatment doses ranged from 4 to 12?mg. Clinical trials may be warranted to explore the potential use of naltrexone in people with these debilitating illnesses which currently have no licensed treatments available.
History
Publication status
- Published
File Version
- Published version
Journal
BMJ Case ReportsISSN
1757-790XPublisher
BMJ Publishing GroupExternal DOI
Volume
13Page range
1-5Article number
a232502Event location
EnglandDepartment affiliated with
- Primary Care and Public Health Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2021-09-29First Open Access (FOA) Date
2021-09-29First Compliant Deposit (FCD) Date
2021-09-28Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC